急性髓系白血病维持治疗的应用实践
本文以4个常见临床场景为框架,结合已发表研究和新兴临床数据,讨论急性髓系白血病(AML)缓解后维持治疗的选择策略。作者强调维持治疗策略需根据白血病生物学与风险分层、可靶向突变、初始治疗方式、体能状态及异基因干细胞移植可行性进行个体化决策。
要点
- 维持治疗策略应基于白血病生物学与风险分层、可靶向突变、初始治疗方式、体能状态及移植可行性个体化决定。
- 多数AML患者经强化或非强化诱导可达初始缓解,但维持长期缓解和降低复发风险仍是关键挑战。
- 多种药物的维持治疗既往成功不一,近期才被整合入标准治疗。
核心结论
- 维持治疗策略的选择是个体化决策,基于白血病生物学与风险分层、可靶向突变的存在、初始治疗方式、体能状态及异基因干细胞移植的可行性。
研究设计与样本
- 本文为「How I use」类临床实践综述,基于已发表研究和新兴临床数据,通过4个常见临床场景讨论AML缓解后维持治疗。
主要发现
- 过去十年AML结局显著改善,得益于靶向白血病细胞多种弱点的创新疗法获批、干细胞移植可及性扩大及移植安全性提高。
- 多数接受强化或非强化诱导方案的AML患者可达初始缓解,但维持长期缓解和降低复发风险仍是关键挑战。
- 使用多种药物的维持治疗策略成功不一,近期才被整合入标准治疗。
临床怎么用
- 作者以4个常见临床场景讨论其对AML维持治疗的 approach,强调依据白血病生物学与风险分层、可靶向突变、初始治疗方式、体能状态及异基因干细胞移植可行性个体化选择具体策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes for acute myeloid leukemia (AML) have improved significantly in the past decade with the approval of novel therapeutics targeting diverse vulnerabilities of leukemic cells, expanded access to stem cell transplantation, and improved safety of transplantation. Although attainment of initial remission is now an expected outcome in most patients with AML receiving intensive or nonintensive induction regimens, maintaining long-term remission and decreasing the risk of relapse remain critical challenges. Maintenance approaches using assorted agents have yielded variable success and only recently have been integrated to the standard of care. We present 4 commonly encountered clinical scenarios that highlight challenges facing physicians as they care for patients with AML in remission and contemplate using postremission maintenance. Using published studies and emerging clinical data, we discuss our approach to maintenance treatment in AML, emphasizing that selection of a specific strategy is an individualized decision based on leukemia biology and risk stratification, presence of targetable mutations, initial treatment approach, performance status, and feasibility of allogeneic stem cell transplantation.
引用
- Roboz GJ, Canaani J. How I use maintenance therapy in acute myeloid leukemia. Blood. 2025. PMID: 39374534. doi:10.1182/blood.2024024010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。